Tech Company Financing Transactions

Seres Therapeutics Funding Round

Seres Therapeutics secured a $10 million Series B financing round on 6/9/2014. Investors included Flagship Pioneering, Alexandria Venture Investments and Enso Ventures.

Transaction Overview

Company Name
Seres Therapeutics
Announced On
6/9/2014
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series B
Investors

Flagship Pioneering (Lead Investor) (David Berry)

Alexandria Venture Investments

Enso Ventures

Mayo Medical Ventures (Heidi Nelson)

Proceeds Purpose
Seres will use the Series B proceeds to advance its rapidly growing pipeline of Ecobiotic therapeutics including its lead candidate, SER-109, which is currently in clinical testing for the treatment of recurrent C. difficile.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Sidney St.
Cambridge, MA 02139
USA
Phone
(617) 945-9626
Website
www.serestherapeutics.com
Email Address
[email protected]
Overview
Seres Therapeutics (NASDAQ: MCRB) is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis.
Profile
Seres Therapeutics LinkedIn Company Profile
Social Media
Seres Therapeutics Company Twitter Account
Company News
Seres Therapeutics News
Facebook
Seres Therapeutics on Facebook
YouTube
Seres Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Roger Pomerantz
  Roger Pomerantz LinkedIn Profile  Roger Pomerantz Twitter Account  Roger Pomerantz News  Roger Pomerantz on Facebook
Chief Financial Officer
Eric Shaff
  Eric Shaff LinkedIn Profile  Eric Shaff Twitter Account  Eric Shaff News  Eric Shaff on Facebook
Chief Medical Officer
Michele Trucksis
  Michele Trucksis LinkedIn Profile  Michele Trucksis Twitter Account  Michele Trucksis News  Michele Trucksis on Facebook
Chief Scientific Officer
David Cook
  David Cook LinkedIn Profile  David Cook Twitter Account  David Cook News  David Cook on Facebook
Chief Technical Officer
John Aunins
  John Aunins LinkedIn Profile  John Aunins Twitter Account  John Aunins News  John Aunins on Facebook
VP - Bus. Development
Henry Rath
  Henry Rath LinkedIn Profile  Henry Rath Twitter Account  Henry Rath News  Henry Rath on Facebook
VP - General Counsel
Thomas DesRosier
  Thomas DesRosier LinkedIn Profile  Thomas DesRosier Twitter Account  Thomas DesRosier News  Thomas DesRosier on Facebook
VP - Operations
Carol Cullinan
  Carol Cullinan LinkedIn Profile  Carol Cullinan Twitter Account  Carol Cullinan News  Carol Cullinan on Facebook
VP - R & D
Matthew Henn
  Matthew Henn LinkedIn Profile  Matthew Henn Twitter Account  Matthew Henn News  Matthew Henn on Facebook
VP - Regulatory Affairs
Barbara McGovern
  Barbara McGovern LinkedIn Profile  Barbara McGovern Twitter Account  Barbara McGovern News  Barbara McGovern on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/9/2014: Avitide venture capital transaction
Next: 6/9/2014: Medoozie venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.